Evidence map›Paper›PMID 33844498›Full record

ArticleACS chemical neuroscience2021

The High Affinity Dopamine D

Sivan Subburaju, Anna W Sromek, Philip Seeman, John L Neumeyer

Open access · greenAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Characterization of [ACS omega · 2026
    Article
  3. Synthesis and evaluation of aporphinoid 5-HTBioorganic & medicinal chemistry letters · 2025
    Article
  4. Natural Product-Inspired Dopamine Receptor Ligands.Journal of medicinal chemistry · 2024
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Sivan SubburajuDivision of Basic Neuroscience, Medicinal Chemistry Laboratory, McLean Hospital, Belmont, Massachusetts 02478, United States.ORCID 0000-0003-3111-9859
Anna W SromekDivision of Basic Neuroscience, Medicinal Chemistry Laboratory, McLean Hospital, Belmont, Massachusetts 02478, United States.
Philip SeemanDepartments of Pharmacology and Psychiatry, University of Toronto, 260 Heath St. West, unit 605, Toronto, Ontario M5P 3L6, Canada.
John L NeumeyerDivision of Basic Neuroscience, Medicinal Chemistry Laboratory, McLean Hospital, Belmont, Massachusetts 02478, United States.ORCID 0000-0003-2287-9864
Harvard University · USUniversity of Toronto · CA

Funding

Preclinical Validation of Novel High Affinity D2 Receptor Agonists for PET NeuroimagingR44OD024615 · OD · NATURAL PHARMACIA INTERNATIONAL, INC. · PI NEUMEYER, JOHN L · 2017 to 2018
$999k
F_18 Labeled D2 Agonist Ligands for PET Imaging of Dopaminergic DysfunctionR21MH103718 · NIMH · MCLEAN HOSPITAL · PI SROMEK, ANNA WACLAWA · 2014 to 2015
$507k
Development of a Tritiated Agonist Radioligand for the D2 ReceptorR43OD020186 · OD · NATURAL PHARMACIA INTERNATIONAL, INC. · PI NEUMEYER, JOHN L · 2014 to 2014
$148k
NIH HHS R43 OD020186NIH HHS R44 OD024615NIMH NIH HHS R21 MH103718
6 · The paper itself

Abstract

The dopamine D

Indexed as

Dopamine AgonistsNervous System DiseasesAnimalsApomorphineCorpus StriatumDopamineRacloprideRatsReceptors, Dopamine D2Receptors, Dopamine D3ApomorphineDopamineDopamine AgonistsN-n-propyl-2-(3-fluoropropanoxy-11-hydroxynoraporphineRacloprideReceptors, Dopamine D2Receptors, Dopamine D3aporphinedopamine D2high receptorParkinson’s diseaseschizophreniatritiated radioligand

Identifiers

PMID33844498
PMCPMC8426090
OpenAlexW3154969302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.